

Appendix B

Checklist for randomized clinical trial design

- 1 Selection description—clear portrayal of patients studied
- 2 Reject log—record of eligible population *not* accepted for the trial
- 3 Withdrawals—dropouts listed by diagnosis, treatment, and reason for withdrawal
- 4 Therapeutic regimens defined—includes timing, amount of daily therapies and all (additional) allowable therapies
- 5 Control regimen—placebo appearance and taste
- 6 Masking procedures
 - a Randomization masking—unpredictability of upcoming treatment assignment
 - b Masking of patients—therapy unidentified
 - c Masking of physicians—therapy unidentified
 - d Masking of physicians and patients—ongoing results of the trial are hidden
- 7 Testing procedures
 - a Sizing the study—prior estimate of number of patients required (Δ , and risk levels α and β)
 - b Distribution of pretreatment variables—known prognostic features by treatment category
 - c Evaluation of masking—physicians and patients queried at the end of the study
 - d Compliance—objective methods of verifying conforming behaviour of patients and physicians
 - e Biological equivalent—attempts to measure therapeutic agent in its active form (after absorption or injection)
- 8 Statistical analysis
 - a Statistical significance of end points—both test statistic and observed probability stated
 - b β estimate—discussion of Type II error
 - c Statistical inference—confidence limits, life-table or time-series analysis, regression analyses or correlations
- 9 Handling of withdrawals—convention adopted for withdrawals
- 10 Side effects—report and discuss side effects of therapies
- 11 Retrospective analyses—post hoc analysis of results in sub-groups with due caution concerning conclusion
- 12 Masking of statistician—presentation of data to analyst in coded form.

- 13 Problem of multiple looks—consider influence of multiple analyses of accumulating data
 - 14 Supplementary data
 - a Dates of starting and stopping accessions
 - b Results of pre-randomization data analysis—evaluation of baseline comparability of study groups
 - c Tabulation of events employed as end-points for each treatment
 - d Timing of events—event times (e.g. outcomes, withdrawals) given to permit construction of a plot of outcome against time
- (Compiled by Chalmers and co-workers)